Approval for the contak renewal tr.  The device is indicated s follows:  the contak renewal tr pulse generator is indicated for patients who have moderate to severe heart failure (nyha class iii/iv) including left ventricular dysfunction (ef <= 35%) and qrs duration >= 120 ms and remain symptomatic despite stable, optimal heart failure drug therapy (as defined in the clinical trials section).  The device provides atrial-ventricular tracking modes to help preserve av synchrony, and adaptive-rate pacing for patients who would benefit from adjusted pacing rates concurrent with physical activity.